Clinically relevant markers of mesothelioma, transcriptional and metabolic profiles, as well as status of the tumor suppressor genes CDKN2A and NF2, the ‘gatekeeper' in MM development,32 were examined in the primary cell lines and compared with those of two widely used commercial cell lines. This evidence concerns the gene CDKN2A and mesothelioma.